Effects of propofol on early and late cytokines in lipopolysaccharideinduced septic shock in rats

Sha Li, Hongguang Bao, Liu Han, Lele Liu

Department of Anesthesiology, Nanjing First Hospital Affiliated to Nanjing Medical University, Nanjing 210006, Jiangsu Province, China Received 10 May 2010

INTRODUCTION

Sepsis and septic shock are common problems in the intensive care unit and carry a very high mortality rate. Various complications that accompany sepsis, such as disseminated intravascular coagulation (DIC) and acute respiratory distress syndrome (ARDS), are refractory to therapy, even with current advanced therapeutic methods. Sepsis is potentially fatal if not treated appropriately[1,2], and many clinical therapies, including anti-inflammatory strategies and fluid replacement, have been used in recent years for treatment of sepsis[3,4]. However, the effectiveness of these strategies is largely unproven, and the morbidity and mortality associated with sepsis are still increasing. As a consequence, it is vital that we find new interventions to treat sepsis.

It has been demonstrated that high mobility group box 1 (HMGB1) protein is an important late-phase mediator in the pathogenesis of sepsis[5]. HMGB1 is a non-histone nuclear protein originally identified as an important factor in the regulation of genetic information by facilitating the binding of transcription factors to their cognate DNA sequences[6]. Wang et al. found that HMGB1 could be actively released from necrotic or damaged cells, or secreted by activated monocytes/macrophages. It also could bind to the receptor for advanced glycation end-products (RAGE), allowing transduction of the signal[7]. Moreover, the release of HMGB1 into the extracellular space is controlled by pro-inflammatory cytokines[8].

Propofol (PPF) is a sedative-hypnotic intravenous anesthetic drug, which is widely used in the intensive care unit as it can be easily titrated and offers the prospect of rapid recovery. When used for sedation or induction and maintenance of anesthesia, PPF has been shown to have a number of hemodynamic effects, including substantial reductions in systemic vascular resistance, heart rate, stroke volume and cardiac output[9,10]. When PPF was used for induction and maintenance of anesthesia in septic sheep, the hemodynamic parameters were reduced compared to those in non-anesthetized septic sheep[11]. Recently, several investigators have reported that PPF inhibited the production of lipopolysaccharide (LPS)-induced tumor necrosis factor-α (TNF-α) and other pro-inflammatory cytokines in endotoxemic rats[12,13]. However, the relationship between PPF and HMGB1 has not yet been determined. We hypothesized that PPF could reduce the levels of pro-inflammatory cytokines and HMGB1 in serum, which in turn could prevent LPS-induced inflammatory responses. To test this hypothesis, we examined the effects of PPF on LPS-induced sepsis in a rat model in this study.

MATERIALS AND METHODS

Animals and materials

Thirty-six male Wistar rats, weighing (315±50) g, were tested in this study. The experimental protocol was approved by the Animal Care Committee of Nanjing Medical University, and the care and handling of the animals were in accordance with National Institutes of Health guidelines. All animals were provided with clean food and water. LPS used in this study was derived from Escherichia coli endotoxin (serotype: O111:B4; Sigma, USA) and dissolved in sterile saline. PPF (AstraZeneca, Italy) was a 1% solution and EDTA-free.

Experimental protocols

The animals were randomly assigned to three groups. All of the rats were anesthetized with an intraperitoneal injection of 10% chloral hydrate (0.4 mL/100g). Control group: rats received 0.9% NaCl [10 mg/kg bolus, followed by infusion at 10 mg/(kg·h)] through the left femoral vein cannula 1 h before intravenous administration of 0.9% NaCl into the tail vein (7.5 mg/kg). PPF+LPS group: PPF [10 mg/kg bolus, followed by infusion at 10 mg/(kg·h)] was infused continuously through the left femoral vein cannula 1 h before injection of LPS (7.5 mg/kg) into the tail vein. LPS group: rats received an intravenous injection of 0.9% NaCl through the left femoral vein cannula 1 h before injection of LPS (7.5 mg/kg) into the tail vein. The right femoral artery was cannulated to monitor mean arterial pressure (MAP) and heart rates (HR). The mortality of rats in each group was determined at 24 h after LPS injection.

Measurement of plasma cytokine levels

At 4, 8, 12 and 24 h after administration of LPS, whole blood was drawn from the right femoral artery (1.0 mL each). The plasma was immediately separated by centrifugation at 1,800 g for 15 min at 4°C, and then divided into aliquots and stored at -20°C until assayed. The levels of pro-inflammatory cytokines [interleukin 6 (IL-6) and TNF-α] and HMGB1 in plasma were quantified using enzyme-linked immunosorbent assays (ELISA) kits (American R&D and Bender Medsystems, USA).

Statistical analysis

The data were presented as mean±SD. Analysis of variance (ANOVA) was used to evaluate the differences between groups at the various time points, and two-way analysis of variance for repeated measurements with multiple comparisons (Bonferroni t). A P value of less than 0.05 was considered statistically significant. Statistical analyses were performed using the SPSS 16.0 software package.

RESULTS

Hemodynamic parameters and mortality rates

No significant differences were noted in baseline HR or MAP among the groups (Fig. 1). An endotoxin injection reduced MAP in both the LPS group and PPF+LPS group, while MAP remained unchanged in the control group. At 24 h after the administration of LPS, MAP decreased by 5.0%, 72.6% and 43.5% in the control group, LPS group and PPF+LPS group, respectively. There were significant differences in MAP between the LPS group and PPF + LPS group at 16, 18, 20, 22 and 24 h time points (P ＜ 0.05).

There were no significant differences in HR among the groups for the first 6 h of the experiment (Fig. 1). In the LPS group, HR significantly increased at 8 h and then gradually decreased. This decrease was statistically significant by 16 h. Thus, there were significant differences in HR at 8, 16, 18, 20, 22 and 24 h time points between the LPS group and PPF+LPS group (P ＜ 0.05).

Rat survival was analyzed at 24 h after the surgical procedures, and mortality after endotoxin injection was 58.3%, 25.0% and 0% for the LPS, PPF + LPS and the control group, respectively (Fig. 2). The mortality in the PPF pretreatment group (PPF+LPS) group was significantly lower than that in the LPS group (P ＜ 0.01).

Fig. 1 MAP (A) and HR (B) at baseline and after LPS or saline injection in different groups.

Fig. 2 Survival curves for LPS, PPF+LPS and control groups.

Plasma cytokine concentrations

Plasma level of IL-6 increased in the LPS group, while pretreatment with PPF significantly decreased IL-6 level. At 4, 8 and 12 h after LPS administration, the serum levels of IL-6 were significantly lower in the PPF+ LPS group than those in the LPS group (P ＜ 0.05, see Table 1). Plasma level of TNF-α also increased after LPS treatment. Serum TNF-α level was significantly lower in the PPF+LPS group compared to the LPS group at 4 h after LPS administration (P ＜ 0.05, see Table 2). Plasma HMGB1 level increased over time after LPS administration in the LPS and PPF+LPS group. Pretreatment with PPF resulted in lower HMGB1 level at 8, 12 and 24 h after LPS administration compared to the LPS group (P ＜ 0.05, see Table 3).

DISCUSSION

Injection of endotoxin alone is the most common method to duplicate septic shock in rats. Previous studies have shown that PPF inhibited inflammatory responses during endotoxemia and sepsis[12,13]. PPF can also attenuate the base deficit and activation of neutrophils in endotoxemia, which suggest that PPF may prevent the development of metabolic acidosis during endotoxemia[14]. However, there were few reports about the effect of PPF on mortality in response to endotoxin-induced shock, especially within 24 h after an endotoxin injection. The study presented here clearly demonstrated that pretreatment with PPF reduced the mortality of rats at 24 h after endotoxin injection.

Table 2 Plasma TNF-α concentration (pg/mL, n = 12)

Table 3 Plasma HMGB1 concentration (μg/mL, n = 12)

PPF is a popular intravenous anesthetic, and is increasingly used in critically ill septic patients[15]. Several publications demonstrated that PPF has a beneficial effect in experimental models of septic shock[16,17]. In our study, PPF administration inhibited development of hypotension, moderately regulated the HR and suppressed the levels of pro-inflammatory cytokines, and the results were in accordance with a previous study[18]. Cytokines have been implicated as important factors in the pathophysiology of endotoxic shock and the development of cardiovascular dysfunction in endotoxemia[19,20]. Therefore, we measured plasma cytokine concentrations to investigate the mechanism by which PPF could reduce mortality in endotoxic shock. We found that endotoxin not only provoked the elevation of pro-inflammatory cytokines such as TNF-α and IL-6 but also the late cytokine--HMGB1 concentration in the plasma in septic rats. By contrast, in the presence of PPF administration, there was an inhibitory effect on endotoxin-induced production of proinflammatory cytokines and HMGB1.

Since TNF-α is considered to play a key role in the pathogenesis of sepsis and septic shock, TNF-α is an important component of the pro-inflammatory cytokines during the early stages of septic shock. Therefore, we measured the plasma TNF-α level in our study. Previously, measurement of IL-6 level enabled us to accurately predict individuals who were at significant risk of sepsis[21], so we also measured IL-6 concentrations. It has recently been demonstrated that the HMGB1 protein is an important late-phase mediator in the pathogenesis of sepsis[7]. Anti-HMGB1 treatment, with either antibodies, specific antagonists or other pharmacological agents, is beneficial in many preclinical inflammatory disease models, and alleviates the severity of such diseases and reduces their mortality[22]. We found that the plasma levels of TNF-α and IL-6 in LPS-induced septic rats were suppressed by PPF. Moreover, PPF also suppressed the plasma level of HMGB1. However, we did not measure HMGB1 mRNA expression, which may be a limitation of this study.

Wang et al.[7]reported that LPS, TNF-α or IL-1 can stimulate the production of HMGB-1 by monocytes. They also found that there was a reciprocal functional relationship between the activities of the early (TNF-α and IL-1) and late (HMGB-1) cytokines[23], which apparently meant that HMGB-1 could participate in the "cross-talk" for the propagation and amplification of downstream pro-inflammatory responses. In our study, we found that the changes in the plasma concentrations of TNF-α, IL-6 and HMGB1 were always consistent in both the PPF+LPS group and LPS group, which was in agreement with the literature[7,23]. The above data indicated that pro-inflammatory cytokines and HMGB1 contributed to the effects of sepsis.

Some important questions remain unanswered: what are the actual mechanisms responsible for the hemodynamic effects of PPF, and what is the mechanism by which PPF mediates its protective effect on pro-inflammatory cytokines and HMGB1. In a recent study, Song et al.[24]indicated PPF suppressed hepatic NF-κB activation, consequently inhibiting the transcription and translation of pro-inflammatory cytokines during polymicrobial sepsis. Whether PPF reduces the levels of HMGB1 in plasma through suppression of the NFκB activation or by other signaling pathways remains to be further studied.

PPF was carried in a lipid emulsion in the present study. Several studies on the relationship between lipids and endotoxemia have been reported. Gordon et al.[25]found that patients who are critically ill from a variety of causes have extremely low cholesterol and lipoprotein concentrations. Correction of the hypolipidemia by a reconstituted high density lipoprotein preparation offers a new strategy for the prevention and treatment of endotoxemia. The ability of lipids to reduce cytokine production in vitro after endotoxin stimulation has been reported[25,26]. In addition, infusions of reconstituted apolipoprotein A-I, chylomicrons or high-density lipoprotein have been shown to decrease TNF-α release and to attenuate shock in animal models[27-29]. However, Tobias et al.[30]reported that lipids may be less effective in neutralizing endotoxin in the acute phase. Our study did not investigate the relationship between lipids alone and endotoxemia, and further study of PPF, lipids alone and endotoxemia are required.

Pan et al.[31]found that chloral hydrate could significantly attenuate acute inflammation in mice treated with LPS/D-GalN and zymosan A. In this study, we also used chloral hydrate as the anesthetic, but the dose we used here was lower than that used by Pan et al.[31], and the rats were anesthetized by intraperitoneal injection, not by intravenous injection. Chloral hydrate has only anaesthetic and sedative effects on rats at the dose we used; therefore, the anti-inflammatory effect we found was induced by PPF but not by chloral hydrate.

Critically ill patients in sepsis/septic shock often suffer a high degree of stress due to pain and anxiety and the organ specific response to sepsis. Achieving an adequate level of sedation will enable the doctors to manage these patients. Our study suggests that PPF may be of benefit by preventing the inflammatory effects and sedating septic patients. Further investigations and clinical trial are needed.

In summary, the study presented here shows that pretreatment with PPF before LPS injection significantly reduced the mortality rate, and attenuated proinflammatory cytokine and HMGB1 responses in rats. These findings suggest that PPF may be beneficial for the treatment of sepsis.

[1] Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348:1546-54.

[2] Wyncoll LA, Evans TW. Acute respiratory distress syndrome. Lancet 1999; 354:497-501.

[3] Opal SM, Fisher CJ Jr, Dhainaut JF, Vincent JL, Brase R, Lowry SF, et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo controlled, multicenter trial. Crit Care Med 1997;25:1115-24.

[4] Abraham E, Wunderink R, Silverman H, Perl TM, Nasraway S, Levy H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. JAMA 1995;273:934-41.

[5] Wang H, Yang H, Tracey KJ. HMGB1 as a late mediator of lethal systemic inflammation. Am J Respir Crit Care Med 2001;164:1768-73.

[6] Bustin M. Regulation of DNA dependent activities by the functional motifs of the high-mobility-group chromosomal proteins. Mol Cell Biol 1999;19:5237-46.

[7] Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999;285:248-51.

[8] Wang H, Vishnubhakat JM, Tracey KJ, Zhang M, Ombrellino M, Sama A, et al. Proinflammatory cytokines(tumor necrosis factor and interleukin 1) stimulate release of high mobility group protein-1 by pituicytes. Surgery 1999;126:389-92.

[9] Nimmo GR, Mackenzie SJ, Grant IS. Hemodynamic and oxygen transport effects of propofol infusion in critically ill adults. Anaesthesia 1994;4:485-9.

[10] Steinbacher DM. Propofol: a sedative-hypnotic anesthetic agent for use in ambulatory procedures. Anesth Prog 2001;48:66-71.

[11] Booke M, Armstrong C, Hinder F, Conroy B, Traber LD, Traber DL. The effects of propofol on hemodynamics and renal blood flow in healthy and in septic sheep, and combined with fentanyl in septic sheep. Anesth Analg 1996; 82:738-43.

[12] Takemoto Y. Dose effects of propofol on hemodynamic and cytokine responses to endotoxemia in rats. J Anesth 2005; 19:40-4.

[13] Hsu BG, Yang FL, Lee RP, Peng TC, Chen HI. Effects of post-treatment with low-dose propofol on inflammatory responses to lipopolysaccharide-induced shock in conscious rats. Clin Exp Pharmacol Physiol 2005;32:24-9.

[14] Taniguchi T, Yamamoto K, Ohmoto N, Ohta K, Kobayashi T. Effects of propofol on hemodynamic and inflammatory responses to endotoxemia in rats. Crit Care Med 2000;28:1101-6.

[15] Marik PE. Propofol: therapeutic indications and sideeffects. Curr Pharm Des 2004;10:3639-49.

[16] Taniguchi T, Kanakura H, Takemoto Y, Kidani Y, Yamamoto K. Effects of ketamine and propofol on the ratio of interleukin-6 to interleukin-10 during endotoxemia in rats. Tohoku J Exp Med 2003;200:85-92.

[17] Takao Y, Mikawa K, Nishina K, Obara H. Attenuation of acute lung injury with propofol in endotoxemia. Anesth Analg 2005; 100:810-6.

[18] Taniguchi T, Yamamoto K. Anti-inflammatory effects of intravenous anesthetics on endotoxemia. Mini Rev Med Chem 2005;5:241-5.

[19] Kuhns DB, Alvord WG, Gallin JI. Increased circulating cytokines, cytokine antagonists, and E-selectin after intravenous administration of endotoxin in human. J Infect Dis 1995;171:145-52.

[20] Damas P, Reuter A, Gysen P, Demonty J, Lamy M, Franchimont P. Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans. Crit Care Med 1989;17:975-8.

[21] Remick DG, Bolgos GR, Siddiqui J, Shin J, Nemzek JA. Six at six: interleukin-6 measured 6 h after the initiation of sepsis predicts mortality over 3 days. Shock 2002;17:463-7.

[22] Yang H, Tracey KJ. Targeting HMGB1 in inflammation. Biochim Biophys Acta 2010;1799:149-56.

[23] Andersson U, Wang H, Palmblad K, Aveberger AC, Bloom O, Erlandsson-Harris H, et al. High mobility group 1 protein (HMGB1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med, 2000;192: 565-70.

[24] Song XM, Wang YL, Li JG, Wang CY, Zhou Q, Zhang ZZ, et al. Effects of propofol on pro-inflammatory cytokines and nuclear factor kappaB during polymicrobial sepsis in rats. Mol Biol Rep 2009;36:2345-51.

[25] Gordon BR, Parker TS, Levine DM, Saal SD, Wang JC, Sloan BJ, et al. Low lipid concentrations in critical illness: Implications for preventing and treating endotoxemia. Crit Care Med 1996;24:584-9.

[26] Cavaillon JM, Fitting C, Haeffner-Cavaillon N, Kirsch SJ, Warren HS. Cytokine response by monocytes and macrophages to free and lipoprotein-bound lipopolysaccharide. Infect Immun 1990;58:2375-82.

[27] Hubsch AP, Powell FS, Lerch PG, Doran JE. A reconstituted, apolipoprotein A-I containing lipoprotein reduces tumor necrosis factor release and attenuates shock in endotoxemic rabbits. Circ Shock 1993;40:14-23.

[28] Harris HW, Grunfeld C, Feingold KR, Read TE, Kane JP, Jones AL, et al. Chylomicrons alter the fate of endotoxin, decreasing tumor necrosis factor release and preventing death. J Clin Invest 1993;91:1028-34.

[29] Levine DM, Parker TS, Donnelly TM, Walsh A, Rubin AL. In vivo protection against endotoxin by plasma high density lipoprotein. Proc Natl Acad Sci U S A 1993; 90:12040-4.

[30] Tobias PS, Ulevitch RJ. Control of lipopolysaccharide-high density lipoprotein binding by acute phase protein(s). J Immunol 1983;131:1913-6.

[31] Pan QJ, Liu Y, Zheng J, Lu X, Wu S, Zhu P, et al. Protective effect of chloral hydrate against lipopolysaccharide/D-galactosamine-induced acute lethal liver injury and zymosan-induced peritonitis in mice. Int Immunopharmacol 2010;10:967-77.